GlassScriptPhysician profile
Denise L Digregorio
NPI 1861907313
$653.78
in general payments reported to CMS, 2019-2025
14 companies · $53.34 in 2025
The $53.34 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $454 · 2022: $146 · 2025: $53.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $53.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $53.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $162.66 | 2021 | |
| Novo Nordisk INC | $155.73 | 2021-2022 | |
| Djo, LLC | $53.34 | 2025 | Cmf |
| Harmony Biosciences LLC | $47.65 | 2021 | |
| Abbvie INC. | $35.96 | 2021 | |
| Boston Scientific Corporation | $32.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.23 | 2022 | |
| Biotronik INC. | $29.27 | 2021 | |
| Currax Pharmaceuticals LLC | $25.56 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.73 | 2021 | |
| Organon LLC | $18.08 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.47 | 2021 | |
| Glaxosmithkline, LLC. | $13.65 | 2022 | |
| Lilly USA, LLC | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Digregorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.